Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Three months ended June 30, 2017
Currency: Indian Rupees (Rs.) with U.S. Dollar (U.S.$) convenience translation at Rs. 64.62 = U.S.$1.00
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Principal markets include India, the United States, Russia, the United Kingdom, and Germany.
Key Financial Metrics
| Metric (in millions) | Q2 2017 (Rs.) | Q2 2017 (U.S.$) | Q2 2016 (Rs.) |
|---|---|---|---|
| Revenues | 33,159 | 513 | 32,345 |
| Gross Profit | 17,097 | 265 | 18,178 |
| Gross Margin | 51.6% | - | 56.2% |
| Operating Profit | 453 | 7 | 1,188 |
| Profit Before Tax | 772 | 12 | 1,707 |
| Net Profit | 591 | 9 | 1,263 |
| Effective Tax Rate | 23.5% | - | 26.0% |
| Cash & Equivalents (End of Period) | 2,825 | 44 | 6,334 |
| Short-term Borrowings | 25,808 | 399 | 43,539 |
| Long-term Borrowings | 24,560 | 380 | 5,449 |
| Net Cash Flow from Operations | (1,979) | (31) | 5,054 |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 3% to Rs. 33,159 million, driven by a 3% increase in Global Generics and a 37% increase in the "Others" segment. This was offset by declines in Proprietary Products (-17%) and PSAI (-1%).
- Profitability Decline: Net profit decreased 53% to Rs. 591 million. Operating profit fell 62% to Rs. 453 million, primarily due to a 6% decline in gross profit and increased R&D expenses.
- Margin Compression: Gross margin decreased from 56.2% to 51.6%. The Global Generics segment margin dropped from 61.3% to 57.7% due to lower realizations in North America and India. PSAI margins contracted significantly from 24.1% to 11.5% due to price declines in key molecules.
- Geographic Performance:
- North America: Revenues decreased 4% due to price erosion and the discontinuation of supply to McNeil Consumer Healthcare, partially offset by new product launches.
- India: Revenues decreased 10% as customers reduced inventory holdings in anticipation of the new Goods and Services Tax (GST) regime effective July 1, 2017.
- Russia: Revenues increased 48% (31% in local currency) driven by volume growth and new product launches.
- Cash Flow: Operating cash flow swung from an inflow of Rs. 5,054 million in Q2 2016 to an outflow of Rs. 1,979 million in Q2 2017, attributed to increased working capital requirements (higher receivables) and lower earnings.
- Debt Structure: Short-term borrowings decreased by Rs. 17,731 million, while long-term borrowings increased by Rs. 19,111 million. This reflects the refinancing of a U.S.$350 million short-term loan (used for ANDA acquisitions) into long-term debt.
Guidance, Outlook, Risks, and Unusual Items
- Regulatory Risks (U.S. FDA): The Company received a warning letter in November 2015 regarding cGMP deviations at three Indian facilities. While the FDA closed the audit of the Miryalaguda API facility in June 2017, re-inspections of other sites resulted in new observations. The Company believes it can resolve these issues but notes that failure to do so could impact new product approvals and shipments.
- Legal Contingencies:
- India Pricing: Ongoing litigation with the National Pharmaceutical Pricing Authority (NPPA) regarding price controls on Norfloxacin and cardiovascular/anti-diabetic formulations. The Company has recorded provisions of Rs. 384 million for potential liabilities related to overcharged amounts.
- U.S. Litigation: Various antitrust and pricing lawsuits (e.g., Nexium, Namenda, pricing/reimbursement class actions) are pending. The Company believes the likelihood of material liability is not probable for most, though outcomes remain uncertain.
- Venezuela Operations: Continued currency devaluation and exchange controls in Venezuela resulted in a foreign exchange loss of Rs. 28 million for the quarter. Revenues from this region were negligible (Rs. 0 million).
- India GST Implementation: The transition to the new GST regime caused a temporary reduction in sales volume in India as customers destocked inventory. The Company anticipates operational adjustments and increased compliance costs.
- Collaborations:
- Curis, Inc.: A collaboration for immuno-oncology targets resulted in a fair value gain of Rs. 637 million recorded in other comprehensive income.
- Merck KGaA: Collaboration on biosimilars continues; Fresenius Kabi is acquiring Merck's biosimilars business, with the collaboration expected to continue under the new ownership.
Key Facts for Investor Verification
- India GST Impact: Verify the extent of the sales volume recovery in India post-July 1, 2017, and the long-term impact of the new tax structure on margins.
- U.S. FDA Resolution: Monitor the status of the remaining FDA observations at the Srikakulam and Duvvada facilities and any potential impact on new product approvals or existing shipments.
- North America Pricing Pressure: Assess the sustainability of revenue growth in the U.S. generics market given the reported price erosion and competitive landscape.
- Debt Refinancing: Confirm the terms and repayment schedule of the new long-term borrowings (U.S.$250 million and EUR 42 million) incurred to replace short-term debt.
- Legal Provisions: Review the adequacy of provisions for the NPPA pricing disputes and the potential exposure from ongoing U.S. antitrust and pricing litigation.